UNSPSC 51312810: Dimetotiazine mesilate

This classification denotes a serotonin antagonist with the molecular formula C19H25N3O2S2.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B28V86NGNK, chemically known as 10h-phenothiazine-2-sulfonamide, 10-(2-(dimethylamino)propyl)-n,n-dimethyl-, monomethanesulfonate but more generally known as dimetotiazine mesilate, which bears US NIH Compound Identifier 25715. European Medicines Agency schedules Dimetotiazine mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01755MIG.

Most nations, for tariff and trade purposes, schedule dimetotiazine mesilate under HS 29350090 and SITC 51580. SMILES: CC(CN1C2CCCCC2SC3C1CC(CC3)S(=O)(=O)N(C)C)N(C)C.CS(=O)(=O)O.

UNSPSC 51312810 Dimetotiazine mesilate is a Commodity code that in recent state and local procurement appears to span naloxone, pharmaceutical supply agreements, and generic multi-source drug products distributed through state health and human services channels. State and local governments buying under this code include county health departments, state health agencies, and cooperative purchasing alliances serving multiple jurisdictions. Seminole County, Florida solicited naloxone and drug deactivation systems through an IFB; the Texas Health and Human Services Commission issued an RFI to assess vendor capacity for direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon. Vendors supplying under this code must meet cGMP certification, Drug Supply Chain Security Act compliance, and FDA requirements; maintain relationships with authorized wholesalers where specified; and provide detailed product information including National Drug Codes, NDCs, and pricing in multiple formats (flat price, net price, WAC-minus).

Recent activity concentrates in the South and Upper Midwest. Seminole County's IFB (issued June 30, 2026, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida, on a two-year contract with one-year renewal option. The Texas HHS RFI (posted April 3, 2026) explored direct-to-manufacturer prescription contracting outside traditional PBM and wholesaler channels, functioning as market intelligence before a formal RFP. MMCAP's RFP (posted January 20, 2026, due March 26, 2026) targeted manufacturers of generic pharmaceuticals and OTC products for multi-state distribution through authorized wholesalers AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson, with contracts effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness. None of these opportunities specified explicit set-asides or disadvantaged-enterprise restrictions. The mismatch between the code name (dimetotiazine mesilate, a specific pharmaceutical compound) and the actual procurements (broad naloxone, generic drug, and pharmacy management programs) suggests limited direct activity for the narrowly defined commodity itself.